Novogenia AG, an international healthcare company specializing in human genetics and personalized health products, has published its issuer report for the first half of 2026, revealing a nuanced financial picture alongside significant strategic developments that could shape its trajectory in the competitive personalized prevention market.
Consolidated revenue for H1 2026 declined 7% year-over-year to EUR 25.7 million, down from EUR 26.5 million in the prior-year period. The decrease was primarily attributed to lower volumes in the pharmaceutical and medical device trading segment due to regulatory changes. However, the core DNA analysis and personalized products segment posted positive revenue growth, signaling resilience in the company's primary business focus. This divergence highlights Novogenia's strategic pivot away from lower-margin trading activities toward higher-value genetic-based offerings.
Cost-saving measures in materials, personnel, and other operating expenses yielded an improvement in operating profit of approximately EUR 2.7 million. Despite this, operating result (EBIT) only improved by 4.1% to EUR -4.7 million, as the prior-year period benefited from one-time effects that boosted other operating income. Consolidated net income for H1 2026 was EUR -2.1 million, compared to a positive EUR 2.0 million in the previous year, which had been bolstered by a significantly higher financial result. As of June 30, 2026, Novogenia held EUR 39.8 million in cash and cash equivalents, down from EUR 71.9 million, but maintains a solid financial position to fund ongoing initiatives.
CEO Dr. Daniel Wallerstorfer commented, "The financial performance in the first half of 2026 did not meet our expectations in all business areas. Thus, we have not yet been able to realize our ambitious growth plans. However, we are encouraged by the positive year-on-year development of our core business in DNA analyses and personalized health products, as well as by a significant reduction in our cost base." He added that the company is working to mitigate the impact of changes to digital platform algorithms on sales channels while managing costs to accelerate core business growth.
Strategically, Novogenia made notable progress. The collaboration with 10X Health Systems was expanded through a joint product pipeline, and the enhanced Methylation Test MGT Plus was launched in the U.S. market. In partnership with G42 in Abu Dhabi, preparations for a Middle East market launch advanced, including product adaptation and Halal certification efforts. The company also launched the Multi-Cancer Check, expanded its preventive healthcare offerings, and introduced a new software platform for its NovoDaily product line to improve development efficiency and turnaround times. Construction began on a new 9,300-square-meter facility in Hallwang near Salzburg, slated for completion in early 2028, which will provide modern laboratory, production, and R&D space.
The renaming from Darwin AG to Novogenia AG, approved at the 2026 Annual General Meeting, was implemented in July 2026, consolidating brand identity and streamlining communication with customers and investors. For more details, visit https://novogenia.com/novogenia-ag. The original release is available on www.newmediawire.com.
Looking ahead, Novogenia's executive board will engage with investors at several conferences. Felix Bausch, CIO, will attend the 5th Zurich Investor Day on September 29, 2026. Dr. Wallerstorfer will present at the Abu Dhabi Future Health Summit from October 20–22, 2026, marking the company's first Middle East appearance, and will oversee the regional product launch. Bausch will also participate in the ODDO BHF Autumn Round Table on October 22, 2026. Both executives will represent Novogenia at the Deutsches Eigenkapitalforum from November 23–25, 2026. These engagements underscore Novogenia's commitment to international expansion and investor transparency.
The H1 2026 report matters because it illustrates Novogenia's transition amid regulatory and market challenges. While overall revenue dipped, the growth in DNA analysis and personalized products validates the company's core strategy. The cost reductions and strategic partnerships, particularly in the U.S. and Middle East, position Novogenia to capitalize on the expanding personalized prevention and healthcare market. The new facility and product launches, such as the Multi-Cancer Check, demonstrate a focus on innovation and scalability. However, the net loss and reduced cash position warrant monitoring, as does the impact of digital platform algorithm changes on sales. Investors and industry stakeholders will look to the upcoming conferences for further clarity on Novogenia's path to profitability and growth.
